Journey Medical Corporation Receives FDA Acceptance for DFD-29 Rosacea Treatment

Monday, 18 March 2024, 13:17

Get the latest update on Journey Medical as they announce the U.S. FDA acceptance of the New Drug Application for DFD-29, a groundbreaking rosacea treatment. The goal date set for November 4, 2024, marks a significant step towards potential approval and market release. Stay informed on the latest developments in the pharmaceutical industry with Journey Medical's promising new treatment.

LivaRava Finance Meta Image — Journey Medical Corporation Receives FDA Acceptance for DFD-29 Rosacea Treatment

Journey Medical Corporation FDA Acceptance

Exciting news from Journey Medical Corporation as the U.S. FDA accepts the New Drug Application (NDA) for DFD-29, a revolutionary treatment for rosacea.

Key Highlights:

DFD-29: A new treatment for rosacea
Goal Date: November 4, 2024

Stay up-to-date with the latest progress in the pharmaceutical industry with this significant development from Journey Medical Corporation.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.